menu

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach Into Current and Emerging Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach Into Current and Emerging Management

11 chapters
Play All
1.25 credits
75 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program to enhance your journey to optimize care for your patients with HER2-gastrointestinal cancers. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kristen K. Ciombor, MD, MSCI
    Associate Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt University Medical Center
    Nashville, TN 

    Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen
    Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen

    Faculty:
    James J. Harding, MD
    Gastrointestinal Oncologist
    Early Drug Development Specialist
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Dr. Harding has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Adaptimmune, AstraZeneca, BMS, Eisai, Elevar, Exelexis, Genoscience, Hepion, Imvax, Jazz, Medivir, Merck (DSMB), QED, RayzeBio, Servier, Tyra, Zymeworks
    Research: BMS, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate, Loxo@Lilly, Novartis, Pfizer, Polaris, Yiviva, Zymeworks

    Filippo Pietrantonio, MD
    Medical Oncologist
    IRCCS National Cancer Institute
    Milan, Italy

    Dr. Pietrantonio has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Astellas, Bayer, BMS, GSK, Ipsen, Johnson & Johnson, Merck Serono, MSD, Pierre-Fabre, Rottapharm, Servier, Takeda
    Research: Agenus, Amgen, AstraZeneca, BMS, Eli Lilly, Incyte

    Kanwal P.S. Raghav, MD, MBBS
    Associate Professor, Department of Gastrointestinal Medical Oncology
    Medical Director, Division of Ambulatory Treatment Centers
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Inc., Eisai, Sanofi, Seagen
    Research: AbbVie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Ann Early has nothing to disclose. 
    • Sara R. Fagerlie, PhD, CHCP, has nothing to disclose. 
    • Elizabeth Lurwick has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies 
    • Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
    • Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
    • Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
    • Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
    • Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credit. Approval is valid until February 29, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program to enhance your journey to optimize care for your patients with HER2-gastrointestinal cancers. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kristen K. Ciombor, MD, MSCI
    Associate Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt University Medical Center
    Nashville, TN 

    Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen
    Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen

    Faculty:
    James J. Harding, MD
    Gastrointestinal Oncologist
    Early Drug Development Specialist
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Dr. Harding has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Adaptimmune, AstraZeneca, BMS, Eisai, Elevar, Exelexis, Genoscience, Hepion, Imvax, Jazz, Medivir, Merck (DSMB), QED, RayzeBio, Servier, Tyra, Zymeworks
    Research: BMS, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate, Loxo@Lilly, Novartis, Pfizer, Polaris, Yiviva, Zymeworks

    Filippo Pietrantonio, MD
    Medical Oncologist
    IRCCS National Cancer Institute
    Milan, Italy

    Dr. Pietrantonio has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Astellas, Bayer, BMS, GSK, Ipsen, Johnson & Johnson, Merck Serono, MSD, Pierre-Fabre, Rottapharm, Servier, Takeda
    Research: Agenus, Amgen, AstraZeneca, BMS, Eli Lilly, Incyte

    Kanwal P.S. Raghav, MD, MBBS
    Associate Professor, Department of Gastrointestinal Medical Oncology
    Medical Director, Division of Ambulatory Treatment Centers
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Inc., Eisai, Sanofi, Seagen
    Research: AbbVie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Ann Early has nothing to disclose. 
    • Sara R. Fagerlie, PhD, CHCP, has nothing to disclose. 
    • Elizabeth Lurwick has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies 
    • Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
    • Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
    • Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
    • Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
    • Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credit. Approval is valid until February 29, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 May 2024